Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.44 |
| ▸ | TLR2 | O60603 | 1/20 | 0.44 |
| ▸ | ERN1 | O75460 | 1/20 | 0.44 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.44 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | G6PD | P11413 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1335770 | 0.77 | CCR1 (0.58) | KDM4EKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL24008926 | 0.77 | KDM4E (0.48) | KDM4EKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL29267446 | 0.77 | PARP1 (0.41) | KDM4EKMT2AMEN1ALDH1A1ERN1 | |
| SCHEMBL8130885 | 0.77 | KDM4E (0.48) | KDM4EKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL8537645 | 0.75 | MEN1 (0.48) | KMT2AMEN1 | |
| SCHEMBL9652279 | 0.75 | MEN1 (0.48) | KMT2AMEN1 | |
| SCHEMBL1257667 | 0.75 | MEN1 (0.51) | KMT2AMEN1 | |
| SCHEMBL28926222 | 0.75 | PIN1 (0.53) | KDM4EKMT2AMEN1ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL8537647 | 0.74 | MEN1 (0.50) | KMT2AMEN1 | |
| SCHEMBL6381401 | 0.73 | HPGDS (0.54) | KDM4EHTR1AADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250011319-A1 | SUBSTITUTED 1H-PYRAZOLO [4,3-c] QUINOLINES, METHODS OF PREPARATION, AND USE THEREOF | LOMOND THERAPEUTICS, INC. | 2025-01-09 | — | — | US | disclosed |
| CN-118076605-A | Substituted 1H-pyrazolo [4,3-c ] quinolines, methods of preparation and uses thereof | 洛蒙治疗公司 | 2024-05-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011319-A1 | SUBSTITUTED 1H-PYRAZOLO [4,3-c] QUINOLINES, METHODS OF PREPARATION, AND USE THEREOF | FLT3, PDXK, PHKG1 | KDM4E 2039/4885KMT2A 863/4885MEN1 2419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.